News Column

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -- SRPT

February 14, 2014



NEW YORK, Feb. 14, 2014 (GLOBE NEWSWIRE) -- Pomerantz LLP has filed a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (Nasdaq:SRPT) and certain of its officers. The class action, filed in United States District Court, District of Massachusetts, and docketed under 14-cv-10225 is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Sarepta between July 24, 2013 and November 12, 2013 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased Sarepta securities during the Class Period, you have until March 28, 2014 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

Sarepta is a biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, Defendants made materially false or misleading statements concerning, among other things, (1) the prospects of the FDA's acceptance for consideration of a New Drug Application ("NDA") for eteplirse, Sarepta's pharmaceutical to treat Duchenne muscular dystrophy, based on its Phase IIb study data set, and (2) the significance of that data set.

On November 11, 2013, shares of Sarepta declined sharply after the Company announced that it was told by the Food and Drug Administration, (FDA) not to file for accelerated approval of eteplirsen. On this news, shares of Sarepta fell $23.40 per share, more than 64.00%, on intraday trading, to a price of $13.16 on November 11, 2013.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT: Robert S. WilloughbyPomerantz LLPrswilloughby@pomlaw.com

Source: Pomerantz LLP


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: GlobeNewswire


Story Tools